Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology.
Adult
Aged
Breast Neoplasms
/ metabolism
Carcinoma, Ductal, Breast
/ metabolism
Carcinoma, Lobular
/ metabolism
Female
Follow-Up Studies
Humans
Lymphatic Metastasis
Middle Aged
Orbital Neoplasms
/ metabolism
Prognosis
Radiotherapy, Intensity-Modulated
Receptor, ErbB-2
/ metabolism
Receptors, Estrogen
/ metabolism
Receptors, Progesterone
/ metabolism
Retrospective Studies
Survival Rate
Treatment Outcome
Breast cancer
Eye
Invasive lobular carcinoma
Metastasis
Ophthalmology
Journal
Breast cancer research : BCR
ISSN: 1465-542X
Titre abrégé: Breast Cancer Res
Pays: England
ID NLM: 100927353
Informations de publication
Date de publication:
26 06 2020
26 06 2020
Historique:
received:
10
02
2020
accepted:
10
06
2020
entrez:
27
6
2020
pubmed:
27
6
2020
medline:
6
11
2020
Statut:
epublish
Résumé
Breast cancer is the most common malignancy to spread to the orbit and periorbit, and the invasive lobular carcinoma (ILC) histologic subtype of breast cancer has been reported to form these ophthalmic metastases (OM) more frequently than invasive ductal carcinomas (IDC). We herein report our single academic institution experience with breast cancer OM with respect to anatomical presentation, histology (lobular vs. ductal), treatment, and survival. We employed the natural language processing platform, TIES (Text Information Extraction System), to search 2.3 million de-identified patient pathology and radiology records at our institution in order to identify patients with OM secondary to breast cancer. We then compared the resultant cohort, the "OM cohort," to two other representative metastatic breast cancer patient (MBC) databases from our institution. Histological analysis of selected patients was performed. Our TIES search and manual refinement ultimately identified 28 patients who were diagnosed with breast cancer between 1995 and 2016 that subsequently developed OM. Median age at diagnosis was 54 (range 28-77) years of age. ER, PR, and HER2 status from the 28 patients with OM did not differ from other patients with MBC from our institution. The relative proportion of patients with ILC was significantly higher in the OM cohort (32.1%) than in other MBC patients in our institution (11.3%, p = 0.007). Median time to first OM in the OM cohort was 46.7 months, and OM were the second most frequent first metastases after bony metastases. After diagnosis of the first distant metastasis of any kind, median survival of patients with ILC (21.4 months) was significantly shorter than that of patients with IDC (55.3 months, p = 0.03). Nine patients developed bilateral OM. We observed a significant co-occurrence of OM and central nervous system metastases (p = 0.0053). The histological analysis revealed an interesting case in which the primary tumor was of a mixed ILC/IDC subtype, while only ILC was present in the OM. OM from breast cancer are illustrative of the difference in metastatic behavior of ILC versus IDC and should be considered when treating patients with ILC, especially in those with complaints of visual acuity changes.
Sections du résumé
BACKGROUND
Breast cancer is the most common malignancy to spread to the orbit and periorbit, and the invasive lobular carcinoma (ILC) histologic subtype of breast cancer has been reported to form these ophthalmic metastases (OM) more frequently than invasive ductal carcinomas (IDC). We herein report our single academic institution experience with breast cancer OM with respect to anatomical presentation, histology (lobular vs. ductal), treatment, and survival.
METHODS
We employed the natural language processing platform, TIES (Text Information Extraction System), to search 2.3 million de-identified patient pathology and radiology records at our institution in order to identify patients with OM secondary to breast cancer. We then compared the resultant cohort, the "OM cohort," to two other representative metastatic breast cancer patient (MBC) databases from our institution. Histological analysis of selected patients was performed.
RESULTS
Our TIES search and manual refinement ultimately identified 28 patients who were diagnosed with breast cancer between 1995 and 2016 that subsequently developed OM. Median age at diagnosis was 54 (range 28-77) years of age. ER, PR, and HER2 status from the 28 patients with OM did not differ from other patients with MBC from our institution. The relative proportion of patients with ILC was significantly higher in the OM cohort (32.1%) than in other MBC patients in our institution (11.3%, p = 0.007). Median time to first OM in the OM cohort was 46.7 months, and OM were the second most frequent first metastases after bony metastases. After diagnosis of the first distant metastasis of any kind, median survival of patients with ILC (21.4 months) was significantly shorter than that of patients with IDC (55.3 months, p = 0.03). Nine patients developed bilateral OM. We observed a significant co-occurrence of OM and central nervous system metastases (p = 0.0053). The histological analysis revealed an interesting case in which the primary tumor was of a mixed ILC/IDC subtype, while only ILC was present in the OM.
CONCLUSIONS
OM from breast cancer are illustrative of the difference in metastatic behavior of ILC versus IDC and should be considered when treating patients with ILC, especially in those with complaints of visual acuity changes.
Identifiants
pubmed: 32586354
doi: 10.1186/s13058-020-01309-3
pii: 10.1186/s13058-020-01309-3
pmc: PMC7318761
doi:
Substances chimiques
Receptors, Estrogen
0
Receptors, Progesterone
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
70Subventions
Organisme : Susan G. Komen
ID : SAC160073
Pays : United States
Organisme : Susan G. Komen
ID : CCR14300865
Pays : United States
Organisme : Susan G. Komen
ID : SAC150021
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA047904
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA180921
Pays : United States
Références
Cancer Med. 2015 Jan;4(1):104-11
pubmed: 25355547
J Clin Oncol. 2015 Sep 1;33(25):2772-9
pubmed: 26215945
Breast Cancer Res. 2004;6(3):R149-56
pubmed: 15084238
Breast Cancer. 2017 Sep;24(5):667-672
pubmed: 28108967
BMC Cancer. 2019 Jan 8;19(1):36
pubmed: 30621656
Invest Ophthalmol Vis Sci. 1999 Aug;40(9):1906-11
pubmed: 10440242
Ann Oncol. 2006 Aug;17(8):1228-33
pubmed: 16740599
Semin Diagn Pathol. 2010 Feb;27(1):49-61
pubmed: 20306830
Ophthalmic Plast Reconstr Surg. 2017 Sep/Oct;33(5):361-366
pubmed: 27749621
AJR Am J Roentgenol. 2014 May;202(5):1140-8
pubmed: 24758672
Biomed Res Int. 2015;2015:574086
pubmed: 26078956
PLoS One. 2017 Sep 1;12(9):e0182397
pubmed: 28863134
Arch Ophthalmol. 1974 Oct;92(4):276-86
pubmed: 4412321
Br J Ophthalmol. 1998 Oct;82(10):1159-61
pubmed: 9924304
Breast Dis. 2019;38(3-4):85-91
pubmed: 31640079
Clin Exp Ophthalmol. 2017 Aug;45(6):606-612
pubmed: 28181367
Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):3944-8
pubmed: 27479811
Asian Pac J Cancer Prev. 2016;17(S3):43-6
pubmed: 27165206
Contemp Oncol (Pozn). 2015;19(4):284-9
pubmed: 26557776
Ophthalmic Plast Reconstr Surg. 2001 Sep;17(5):346-54
pubmed: 11642491
Curr Eye Res. 2015 May;40(5):541-8
pubmed: 25260172
Geburtshilfe Frauenheilkd. 2017 Jun;77(6):660-666
pubmed: 28757653
Health Qual Life Outcomes. 2009 Feb 25;7:18
pubmed: 19243624
BMJ Case Rep. 2018 Oct 12;2018:
pubmed: 30317191
Breast Cancer Res. 2015 Jan 30;17:12
pubmed: 25849106
Orbit. 2020 Apr 27;:1-5
pubmed: 32340504
J Clin Oncol. 2008 Jun 20;26(18):3006-14
pubmed: 18458044
Cancer Res. 2015 Dec 15;75(24):5194-201
pubmed: 26670560
JAMA. 2003 Mar 19;289(11):1421-4
pubmed: 12636465